Since 5-HT mediates accelerated atherosclerosis in diabetes, pharmacological inhibition of the 5-HT receptor presents an attractive therapeutic strategy for patients with diabetes to attenuate the development of nephropathy and macrovascular complications. Here, HTR5A is linked to kidney disorder.